Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI), which is changing its corporate name to Axe Compute Inc. with an expected ticker transition to AGPU, generates news at the intersection of AI‑driven oncology, capital markets activity, and digital asset‑enabled AI infrastructure. Company announcements emphasize its use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for cancer patients, as well as its newer digital asset treasury strategy focused on ATH, the native utility token of the Aethir network.
News updates frequently cover financial results and corporate updates, including quarterly earnings releases, shareholder letters, and discussions of operating performance. These communications often describe progress in validating proprietary technologies, such as the PEDAL AI platform and the ChemoFx live‑cell tumor profiling assay, along with efforts to expand the availability of ChemoFx in the United States and prepare for a de novo launch in Europe.
Investors following POAI can also expect transaction and financing news, such as private placements involving cash and digital assets, reverse stock split announcements, at‑the‑market offering updates, and standby equity purchase agreements. Recent disclosures describe substantial private investment in support of the company’s digital asset treasury strategy, as well as Nasdaq compliance updates related to stockholders’ equity and bid price requirements.
Another recurring theme in the news flow is strategic partnerships and governance developments. Examples include the strategic collaboration with Every Cure on drug repurposing, collaborations related to 3D liver toxicity models, and appointments of new board members and senior leaders to support the digital asset treasury and AI initiatives. Updates on the evolution of the company’s business model, including the creation of a Strategic Compute Reserve through ATH holdings on the Aethir ecosystem, are also highlighted.
For readers and investors, the POAI news page provides a consolidated view of these developments, allowing closer tracking of the company’s oncology‑focused AI activities, its digital asset strategy, and key regulatory and listing milestones.
Predictive Oncology Inc. (NASDAQ: POAI) announced the successful closure of a transaction leading to gross cash proceeds of approximately $2.2 million from warrant exercises. The transaction involved the exercise of 1,396,826 shares at $1.575 per share, offering new unregistered warrants at $1.80 per share valid for five and a half years. The funds will be utilized for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. The new warrants and shares will not be registered under the Securities Act, available only to accredited investors.
Predictive Oncology (NASDAQ: POAI) has made significant strides by fulfilling its first commercial order for specialized ovarian cancer cell culture media. This media, developed by its TumorGenesis division, allows researchers to grow patient-derived ovarian cancer cells more effectively, preserving crucial DNA, RNA, and proteomic signatures. The order was placed by a leading medical institution in New England. This innovative product aims to address the challenges posed by unvalidated media that increases research costs and reproducibility issues, ultimately driving advancements in cancer treatment research.
Predictive Oncology (NASDAQ: POAI) reported Q1 2020 revenues of $295,943, up from $255,241 year-over-year, driven primarily by STREAMWAY unit sales. Gross margins remained strong at 69%. However, net loss increased to $4.5 million from $3.3 million in the same quarter last year. The company is actively pursuing potential acquisitions to bolster its capabilities, including a COVID-19 vaccine development. The operational focus remains on the Helomics and TumorGenesis divisions, emphasizing AI applications in precision medicine.
Predictive Oncology (NASDAQ: POAI) has acquired the assets of Soluble Therapeutics and BioDtech, both subsidiaries of InventaBioTech, for 125,000 shares of common stock, alongside waiving a $1.07 million promissory note. This acquisition enhances Predictive's capabilities in precision medicine and drug formulation. CEO Dr. Carl Schwartz highlighted that the Soluble assets improve service offerings to pharmaceutical and biotech industries, while BioDtech's test allows monitoring of endotoxins, optimizing treatment strategies. These moves aim to bolster revenue prospects and expand the company’s market presence.
Predictive Oncology (NASDAQ: POAI) announced a registered direct offering of 1,396,826 shares of common stock at $1.575 per share, raising approximately $2.2 million. The offering includes unregistered warrants for the same number of shares, exercisable at $1.45 each for five and a half years. The company plans to use $487,000 of the net proceeds to repay debt and the remainder for working capital. The offering is expected to close on May 8, 2020, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.